Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States

Anesthesia and Analgesia

Volumn 116, Issue 5, 2013, Pages 1078-1086

  Brandom, Barbara W ^a   Bina, Saiid ^b   Wong, Cynthia A ^c   Wallace, Tarina ^b   Visoiu, Mihaela ^d   Isackson, Paul J ^e   Vladutiu, Georgirene D ^e   Sambuughin, Nyamkhishig ^b   Muldoon, Sheila M ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Uniformed Services University of the Health Sciences   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDROPYRIDINE RECEPTOR; CAFFEINE; HALOTHANE; RYANODINE RECEPTOR 1;

AMINO ACID SUBSTITUTION; ARTICLE; CACNA1S GENE; CAFFEINE HALOTHANE CONTRACTURE TEST; EXON; FUNCTION TEST; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT HYPERTHERMIA; NUCLEOTIDE SEQUENCE; POPULATION; PRIORITY JOURNAL; RECEPTOR GENE; RYANODINE RECEPTOR 1 GENE; UNITED STATES;

ANESTHETICS, INHALATION; CALCIUM CHANNELS; DNA; EXONS; GENETIC VARIATION; HALOTHANE; HETEROZYGOTE; HUMANS; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTION; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; UNITED STATES;

EID: 84876745830     PISSN: 00032999     EISSN: 15267598     Source Type: Journal    
DOI: 10.1213/ANE.0b013e31828a71ff     Document Type: Article

References (42)

1. Rueffert H, Olthoff D, Deutrich C, Meinecke CD, Froster UG. Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: Identification of three novel mutations. Acta Anaesthesiol Scand 2002;46:692-8
2. Monnier N, Kozak-Ribbens G, Krivosic-Horber R, Nivoche Y, Qi D, Kraev N, Loke J, Sharma P, Tegazzin V, Figarella-Branger D, Roméro N, Mezin P, Bendahan D, Payen JF, Depret T, Maclennan DH, Lunardi J. Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility. Hum Mutat 2005;26:413-25
3. Sambuughin N, Holley H, Muldoon S, Brandom BW, de Bantel AM, Tobin JR, Nelson TE, Goldfarb LG. Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north american population. Anesthesiology 2005;102:515-21
4. Ibarra M CA, Wu S, Murayama K, Minami N, Ichihara Y, Kikuchi H, Noguchi S, Hayashi YK, Ochiai R, Nishino I. Malignant hyperthermia in Japan: Mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. Anesthesiology 2006;104:1146-54
5. Levano S, Vukcevic M, Singer M, Matter A, Treves S, Urwyler A, Girard T. Increasing the number of diagnostic mutations in malignant hyperthermia. Hum Mutat 2009;30:590-8
6. Kraeva N, Riazi S, Loke J, Frodis W, Crossan ML, Nolan K, Kraev A, MacLennan DH. Ryanodine receptor type 1 gene mutations found in the Canadian malignant hyperthermia population. Can J Anaesth 2011;58:504-13
7. Tammaro A, Di Martino A, Bracco A, Cozzolino S, Savoia G, Andria B, Cannavo A, Spagnuolo M, Piluso G, Aurino S, Nigro V. Novel missense mutations and unexpected multiple changes of RYR1 gene in 75 malignant hyperthermia families. Clin Genet 2011;79:438-47
8. Jungbluth H, Sewry CA, Muntoni F. Core myopathies. Semin Pediatr Neurol 2011;18:239-49
9. Sambuughin N, Sei Y, Gallagher KL, Wyre HW, Madsen D, Nelson TE, Fletcher JE, Rosenberg H, Muldoon SM. North American malignant hyperthermia population: Screening of the ryanodine receptor gene and identification of novel mutations. Anesthesiology 2001;95:594-9
10. Sei Y, Sambuughin NN, Davis EJ, Sachs D, Cuenca PB, Brandom BW, Tautz T, Rosenberg H, Nelson TE, Muldoon SM. Malignant hyperthermia in North America: Genetic screening of the three hot spots in the type I ryanodine receptor gene. Anesthesiology 2004;101:824-30
11. Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA, Kaplan RF, Muldoon SM, Nelson TE, Ording H, Rosenberg H, Waud BE, Wedel DJ. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994;80:771-9
12. Larach MG. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Anesth Analg 1989;69:511-5
13. Monnier N, Romero NB, Lerale J, Nivoche Y, Qi D, MacLennan DH, Fardeau M, Lunardi J. An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor. Hum Mol Genet 2000;9:2599-608
14. Vladutiu GD, Isackson PJ, Kaufman K, Harley JB, Cobb B, Christopher-Stine L, Wortmann RL. Genetic risk for malignant hyperthermia in non-Anesthesia- induced myopathies. Mol Genet Metab 2011;104:167-73
15. Jungbluth H, Lillis S, Zhou H, Abbs S, Sewry C, Swash M, Muntoni F. Late-onset axial myopathy with cores due to a novel heterozygous dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscul Disord 2009;19: 344-7
16. Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P. Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 2006;27:977-89
17. Sambuughin N, McWilliams S, de Bantel A, Sivakumar K, Nelson TE. Single-Amino-Acid deletion in the RYR1 gene, associated with malignant hyperthermia susceptibility and unusual contraction phenotype. Am J Hum Genet 2001;69: 204-8
18. McWilliams S, Nelson T, Sudo RT, Zapata-Sudo G, Batti M, Sambuughin N. Novel skeletal muscle ryanodine receptor mutation in a large Brazilian family with malignant hyperthermia. Clin Genet 2002;62:80-3
19. Wehner M, Rueffert H, Koenig F, Olthoff D. Functional characterization of malignant hyperthermia-Associated RyR1 mutations in exon 44, using the human myotube model. Neuromuscul Disord 2004;14:429-37
20. Barone V, Massa O, Intravaia E, Bracco A, Di Martino A, Tegazzin V, Cozzolino S, Sorrentino V. Mutation screening of the RYR1 gene and identification of two novel mutations in Italian malignant hyperthermia families. J Med Genet 1999;36:115-8
21. Galli L, Orrico A, Cozzolino S, Pietrini V, Tegazzin V, Sorrentino V. Mutations in the RYR1 gene in Italian patients at risk for malignant hyperthermia: Evidence for a cluster of novel mutations in the C-Terminal region. Cell Calcium 2002;32:143-51
22. Tammaro A, Bracco A, Cozzolino S, Esposito M, Di Martino A, Savoia G, Zeuli L, Piluso G, Aurino S, Nigro V. Scanning for mutations of the ryanodine receptor (RYR1) gene by denaturing HPLC: Detection of three novel malignant hyperthermia alleles. Clin Chem 2003;49:761-8
23. Wu S, Ibarra MC, Malicdan MC, Murayama K, Ichihara Y, Kikuchi H, Nonaka I, Noguchi S, Hayashi YK, Nishino I. Central core disease is due to RYR1 mutations in more than 90% of patients. Brain 2006;129:1470-80
24. Chan B, Chen SP, Wong WC, Mak CM, Wong S, Chan KY, Chan AY. RYR1-related central core myopathy in a Chinese adolescent boy. Hong Kong Med J 2011;17:67-70
25. Dekomien G, Gencik M, Gencikova A, Klenk Y, Epplen JT. Gene symbol: RYR1. Disease: Malignant hyperthermia. Hum Genet 2005;118:543
26. Monnier N, Marty I, Faure J, Castiglioni C, Desnuelle C, Sacconi S, Estournet B, Ferreiro A, Romero N, Laquerriere A, Lazaro L, Martin JJ, Morava E, Rossi A, Van der Kooi A, de Visser M, Verschuuren C, Lunardi J. Null mutations causing depletion of the type 1 ryanodine receptor (RYR1) are commonly associated with recessive structural congenital myopathies with cores. Hum Mutat 2008;29:670-8
27. Gillies RL, Bjorksten AR, Davis M, Du Sart D. Identification of genetic mutations in Australian malignant hyperthermia families using sequencing of RYR1 hotspots. Anaesth Intensive Care 2008;36:391-403
28. Kaufmann A, Kraft B, Michalek-Sauberer A, Weigl LG. Novel ryanodine receptor mutation that may cause malignant hyperthermia. Anesthesiology 2008;109:457-64
29. Jungbluth H, Müller CR, Halliger-Keller B, Brockington M, Brown SC, Feng L, Chattopadhyay A, Mercuri E, Manzur AY, Ferreiro A, Laing NG, Davis MR, Roper HP, Dubowitz V, Bydder G, Sewry CA, Muntoni F. Autosomal recessive inheritance of RYR1 mutations in a congenital myopathy with cores. Neurology 2002;59:284-7
30. Tilgen N, Zorzato F, Halliger-Keller B, Muntoni F, Sewry C, Palmucci LM, Schneider C, Hauser E, Lehmann-Horn F, Müller CR, Treves S. Identification of four novel mutations in the C-Terminal membrane spanning domain of the ryanodine receptor 1: Association with central core disease and alteration of calcium homeostasis. Hum Mol Genet 2001;10:2879-87
31. Shepherd S, Ellis F, Halsall J, Hopkins P, Robinson R. RYR1 mutations in UK central core disease patients: More than just the C-Terminal transmembrane region of the RYR1 gene. J Med Genet 2004;41:e33
32. Sewry CA, Müller C, Davis M, Dwyer JS, Dove J, Evans G, Schröder R, Fürst D, Helliwell T, Laing N, Quinlivan RC. The spectrum of pathology in central core disease. Neuromuscul Disord 2002;12:930-8
33. Quinlivan RM, Muller CR, Davis M, Laing NG, Evans GA, Dwyer J, Dove J, Roberts AP, Sewry CA. Central core disease: Clinical, pathological, and genetic features. Arch Dis Child 2003;88:1051-5
34. Davis MR, Haan E, Jungbluth H, Sewry C, North K, Muntoni F, Kuntzer T, Lamont P, Bankier A, Tomlinson P, Sánchez A, Walsh P, Nagarajan L, Oley C, Colley A, Gedeon A, Quinlivan R, Dixon J, James D, Müller CR, Laing NG. Principal mutation hotspot for central core disease and related myopathies in the C-Terminal transmembrane region of the RYR1 gene. Neuromuscul Disord 2003;13:151-7
35. Monnier N, Krivosic-Horber R, Payen JF, Kozak-Ribbens G, Nivoche Y, Adnet P, Reyford H, Lunardi J. Presence of two different genetic traits in malignant hyperthermia families: Implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology 2002;97:1067-74
36. McKenney KA, Holman SJ. Delayed postoperative rhabdomyolysis in a patient subsequently diagnosed as malignant hyperthermia susceptible. Anesthesiology 2002;96:764-5
37. Carpenter D, Robinson RL, Quinnell RJ, Ringrose C, Hogg M, Casson F, Booms P, Iles DE, Halsall PJ, Steele DS, Shaw MA, Hopkins PM. Genetic variation in RYR1 and malignant hyperthermia phenotypes. Br J Anaesth 2009;103:538-48
38. Loke JC, MacLennan DH. Bayesian modeling of muscle biopsy contracture testing for malignant hyperthermia susceptibility. Anesthesiology 1998;88:589-600
39. Maile MD, Patel RA, Blum JM, Tremper KK. A case of malignant hyperthermia captured by an anesthesia information management system. J Clin Monit Comput 2011;25:109-11
40. Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 2010;110:498-507
41. Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the caffeine-halothane contracture test, a report from the North American Malignant Hyperthermia Registry. Anesthesiology 1998;88:579-88
42. Ginz HF, Girard T, Censier K, Urwyler A. Similar susceptibility to halothane, caffeine and ryanodine in vitro reflects pharmacogenetic variability of malignant hyperthermia. Eur J Anaesthesiol 2004;21:151-7